Scam Alert: New Fraud Vendors + FDA Warns of Counterfeit

The peptide market remains under pressure: three new fraudulent vendors have been verified on the Vendor Radar in recent weeks, while the U.S. FDA has taken multiple actions against counterfeit and illegal GLP-1 products. For consumers, this means extreme caution is required when sourcing peptides, especially semaglutide and tirzepatide.

Vendor Radar: Three New Scam Vendors Identified

The Peptigraph community has reported and verified three new fraudulent vendors in the past 30 days:

• GH-Labs Store (Shop, 2 verified reports) - reported June 20, 2026
• PeptideXpress.bz (Shop, 3 verified reports) - reported June 18, 2026
• t.me/peplab_deals (Contact/Telegram, 4 verified reports) - reported June 15, 2026

Reported losses amount to approximately 970 USD/EUR and 0.05 BTC. One additional vendor is currently under review. I recommend checking the current Vendor-Radar before any purchase.

FDA Warns of Counterfeit Ozempic in the Supply Chain

In December 2023, the FDA seized dozens of units of counterfeit Ozempic (semaglutide 1 mg injection) that had entered the legitimate U.S. drug supply chain. The counterfeits bore lot number PAR0362. They can be identified by the placement of the expiration date: on counterfeits, it appears to the left of the lot number; on authentic pens, it is positioned above the lot number. The FDA warns that the quality, sterility, and safety of these products are unknown. Earlier counterfeits (lot NAR0074) contained non-sterile needles posing increased infection risk. Learn more in the semaglutide profile.

Import Alert 66-40: Halting Illegal GLP-1 Imports

In September 2025, the FDA dramatically tightened regulations: Import Alert 66-40 (Unapproved Drugs) allows only GLP-1 active ingredients (semaglutide, tirzepatide) from manufacturers on the FDA 503A/503B Bulks List to enter the U.S. All other shipments are detained without physical examination. Concurrently, the FDA issued numerous Warning Letters to companies illegally marketing GLP-1 products as "generics" or "research use only." This also affects tirzepatide and retatrutide.

What Does This Mean for Buyers?

Current developments paint a clear picture: the peptide market - especially for GLP-1 preparations - is increasingly infiltrated by counterfeits, illegal imports, and fraudulent vendors. The FDA emphasizes that untested products may contain unknown ingredients, incorrect dosages, or contaminants. Anyone sourcing peptides should only use vendors who provide batch-specific Certificates of Analysis (COA) from independent laboratories and should be familiar with the quality indicators of high-grade peptides.

Important notice: This article is for educational purposes only and does not constitute medical advice. For health-related questions, please consult a physician or pharmacist. Peptigraph does not sell peptides and does not provide sourcing information.